This result is consistent with those of other reports, in which the VCAN excessive production could be abrogated by the addition of a TGF-β-neutralizing antibody or in the presence of TGF-β receptor and SMAD3-specific inhibitors in ovarian cancer associated fibroblasts 52, 53. This evidence concerns the gene VCAN and ovarian carcinoma.